Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis

Ma, Yun‐Bao; Tian, Zhenjun; Zhang, Wei

doi:10.1007/s00432-012-1285-0

Cited by 117 publications

(89 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a separate report, high miR-125b serum expression was shown to be an independent predictor of poor survival in an analysis of 193 NSCLC patients of various stages (22). A signature of 5 miR gene set has recently been identified by Silva et al as a potential prognostic marker, and was validated in a separate cohort of 78 NSCLC patients and 48 control participants.…”

Section: Micrornas (Mirs)mentioning

confidence: 91%

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Xu‐Welliver¹,

Carbone²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Despite recent advances, non-small cell lung cancer (NSCLC) remains a devastating disease with overall poor prognosis. Major contributing factors include obstacles to diagnosing the disease early in its course during the asymptomatic stage as well as diversity and complexity of its biology underlying tumorigenesis and tumor progression. Advances in molecularly targeted therapies which drives the development of personalized cancer care require precise and comprehensive understanding of tumor biology, not only at the time of diagnosis but also during treatment course and surveillance. As lung tumor tissue can be difficult to obtain without invasive and potentially risky procedures, it is difficult to monitor treatment response with serial tissue biopsies. Development of non-invasive but reliable blood based tumor markers has become an important research area. In this review, we focus on the following circulating biomarkers that have been identified in recent years: circulating tumor cells (CTCs); circulating cell-free nucleic acids, such as circulating tumor DNA (ctDNA) and microRNA (miR); and other biomarkers such as genomic and proteomic features. These biomarkers not only have prognostic values, but also can help guild treatment decisions by monitoring tumor burden, detecting minimal residual disease and/or recurrent disease, as well as monitoring evolution of genetic alterations throughout the treatment course.

show abstract

Section: Micrornas (Mirs)mentioning

confidence: 91%

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Xu‐Welliver¹,

Carbone²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Another study (Yuxia et al, 2012) is suggestive of using these miRNAs as biomarkers as minimally invasive -155, miR-197, miR-182 Up regulated in lung cancer patients serum Zheng et al, 2011 miR-486, miR-30d, miR-1, miR-499 Correlated to Overall Survival Hu et al, 2010. miR-146b, miR-221, miR-155, miR-17-5p, Significantly reduced in serum of Lung Cancer Patients Heegaard et al, 2012 miR-27a, miR-106a miR-92, miR-484, miR-486, miR-328, miR-191, 34 miRNA panel that can differentiate Bianchi et al, 2011 miR-376a, miR-342, miR-331, miR-30c, miR-28, between tumour and normal sera miR-98, miR-17-5p, miR-26b, miR-374, miR-30b, miR-26a, miR-142-3p, miR-103, miR-126, let-7a, let7d, let 7b, miR-32, miR-133b, miR-566, miR-432, miR-223, miR-29a, miR-148a, miR-142-5p, miR-22, miR-148-p, miR-140, miR-139 miR-1254, miR-574-5p Triage tool Foss et al, 2011 miR-21, miR-205, miR-30d, miR-24 Preoperative and post operative levels Le et al, 2012 miR21,miR-210, miR-485-5p…”

Section: Mirna As a Triage Tool For Diagnosticsmentioning

confidence: 99%

Lung Cancer Detection by Screening - Presenting Circulating miRNAs as a Promising Next Generation Biomarker Breakthrough

Ramshankar

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Lung cancer remains a major cause of morbidity and mortality worldwide, accounting for more deaths than any other cause. All the clinical practice guidelines recommended against routine screening for lung cancer have cited lack of robust evidence, at least until a few years back. However, the potential to screen lung cancers has received renewed interest due to superior performance of low dose CT (LD-CT) in detecting early stage cancers. The incremental costs and risks involved due to the invasive procedures in the screened population due to a high false positivity rate questions the use of LD-CT scan as a reliable community based screening tool. There is therefore an urgent need to find a less invasive and a more reliable biomarker that is crucial to increase the probability of early lung cancer detection. This can truly make a difference in lung cancer survival and at the same time be more cost and resource utilization effective. Sampling blood serum being minimally invasive, low risk and providing an easy to obtain biofluid, needs to be explored for potential biomarkers. This review discusses the use of circulatory miRNAs that have been able to discriminate lung cancer patients from disease free controls. Several studies conducted recently suggest that circulating miRNAs may have promising future applications for screening and early detection of lung cancer.

show abstract

“…Recent reports have already given more prominence to the oncogenic aspects of miR125b, claiming that serum miR-125b could be a novel biomarker for screening human tumors, including non-small-cell lung cancer and breast cancer (Wang et al, 2012;Yuxia et al, 2012). Our previous miR array analysis in ES tissue samples has demonstrated the diagnostic potential of miR-125b (Li et al, 2014).…”

Section: Discussionmentioning

confidence: 90%

Circulating miR-125b as a biomarker of Ewing's sarcoma in Chinese children

Nie¹,

Ren²,

Ma³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Previous studies indicated that has an important role in the progression of Ewing's sarcoma (ES). The purpose of the current study was to examine expression changes of miR125b in the serum of ES patients and evaluate if the expression level of miR-125b could serve as a new biomarker for ES. This study was performed on patients who underwent surgical resection at our hospital between 2005 and 2013 after an initial diagnosis of ES. We measured serum miR-125b levels in 63 patients with ES and 126 healthy control patients using a real-time quantitative reverse transcriptase-PCR (qRT-PCR) method. Expression levels of serum miR-125b were distinctly decreased in ES patients when compared with healthy controls (P < 0.001). ES cases that had a poor response to chemotherapy presented a significant down-regulation of miR-125b (P = 0.001). The ROC curve showed that the serum miR-125b could serve as a valuable biomarker for differentiating ES patients from healthy controls with an AUC of 0.879 (95%CI = 0.817-0.924; P < 0.001). At a cut-off value of 2.203 for miR-125b, the sensitivity was 72.8% and the specificity was 87.2% in 19049-19056 (2015) discriminating ES from the controls. Our results indicate that serum miR125b may serve as a useful noninvasive biomarker for ES.

show abstract

Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis

Abstract: We propose that serum miR-125b may represent a novel biomarker in NSCLC patients and that high miR-125b expression is an independent prognostic factor for survival.

Cited by 117 publications

References 16 publications

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Lung Cancer Detection by Screening - Presenting Circulating miRNAs as a Promising Next Generation Biomarker Breakthrough

Circulating miR-125b as a biomarker of Ewing's sarcoma in Chinese children

Contact Info

Product

Resources

About